InvestorsHub on MSN

FDA accepts Cogent’s drug filing for treatment of rare blood disorder

Cogent Biosciences Inc. (NASDAQ:COGT) said the U.S. Food and Drug Administration has accepted its New Drug Application for ...

Cogent Biosciences stock climbs after FDA accepts key drug application

Cogent Biosciences Inc. COGT shares are up on Monday after the U.S. Food and Drug Administration accepted its drug ...

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration ...
newscase

Cogent Biosciences Advances Key Drug Candidate with Strong Clinical Data

Cogent Biosciences recently showcased compelling long-term efficacy data for its lead drug candidate, bezuclastinib, at the 2026 American Academy of Allergy Ast ...
Nasdaq

Cogent Biosciences, Inc. Unveils Preclinical Data from Four Pipeline Programs at AACR 2025 Annual Meeting

Cogent Biosciences, Inc. announced strong preclinical data from four of its therapeutic pipeline programs during the AACR 2025 Annual Meeting in Chicago, showcasing its work on precision therapies for ...